Probi Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Probi şirketinin toplam hissedar öz sermayesi SEK1.4B ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK1.5B ve SEK155.9M dir. Probi 'in FAVÖK'ü SEK3.1M faiz karşılama oranı -0.4 dur. Şirketin SEK349.4M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	-0.4x
Nakit	SEK 349.41m
Eşitlik	SEK 1.37b
Toplam yükümlülükler	SEK 155.86m
Toplam varlıklar	SEK 1.52b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Jul 24

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Jun 26

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

May 05

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Mar 05

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Feb 15

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

Jan 29

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

Jan 11

Have Insiders Been Buying Probi AB (publ) (STO:PROB) Shares?

Dec 22

Has Probi AB (publ)'s (STO:PROB) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PROB 'nin kısa vadeli varlıkları ( SEK561.6M ) kısa vadeli yükümlülüklerini ( SEK89.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: PROB şirketinin kısa vadeli varlıkları ( SEK561.6M ) uzun vadeli yükümlülüklerini ( SEK66.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PROB borçsuzdur.

Borcun Azaltılması: PROB un 5 yıl önce borcu yoktu.

Borç Kapsamı: PROB un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: PROB şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Probi Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Probi AB Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Probi AB (Publ) Launches Probi Sense

New minor risk - Share price stability

Now 21% undervalued

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Now 22% undervalued

Now 22% undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Dividend of kr1.30 announced

Now 21% undervalued after recent price drop

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Third quarter 2023 earnings released: EPS: kr0.56 (vs kr1.09 in 3Q 2022)

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Second quarter 2023 earnings released: kr0.55 loss per share (vs kr1.75 profit in 2Q 2022)

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Insufficient new directors

Upcoming dividend of kr1.30 per share at 0.7% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Now 21% undervalued after recent price drop

Probi AB (publ) Announces Management Changes

Now 25% undervalued after recent price drop

Probi Probiotics Reduce Gut Problems in Connection with Cancer Radiotherapy

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Probi AB (Publ) Approves Dividend for the Financial Year 2021

Chief Executive Officer recently bought kr409k worth of stock

Upcoming dividend of kr1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend, Payable on 12 May 2022

Now 23% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend for the Year 2021

Third quarter 2021 earnings released: EPS kr1.62 (vs kr2.91 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Should You Be Adding Probi (STO:PROB) To Your Watchlist Today?

Estimating The Intrinsic Value Of Probi AB (publ) (STO:PROB)

Consensus EPS estimates fall to kr8.37

Second quarter 2021 earnings released: EPS kr1.39 (vs kr2.37 in 2Q 2020)

Investor sentiment improved over the past week

Is Now The Time To Put Probi (STO:PROB) On Your Watchlist?

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

Upcoming dividend of kr1.10 per share

Price target increased to kr505

Full year 2020 earnings released: EPS kr8.14 (vs kr7.54 in FY 2019)

Probi AB (publ) Announces Three Years Collaboration with La Trobe University

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Probi and Perrigo Sign Extensive Pan-European Agreement for Launch of Probiotic Concepts

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS kr8.14 (vs kr7.54 in FY 2019)

Price target raised to kr455

Revenue beats expectations, earnings disappoint